During the last session, Xilio Therapeutics Inc (NASDAQ:XLO)’s traded shares were 0.31 million, with the beta value of the company hitting -0.25. At the end of the trading day, the stock’s price was $0.75, reflecting an intraday gain of 2.21% or $0.02. The 52-week high for the XLO share is $1.93, that puts it down -157.33 from that peak though still a striking 16.0% gain since the share price plummeted to a 52-week low of $0.63. The company’s market capitalization is $38.62M, and the average intraday trading volume over the past 10 days was 0.27 million shares, and the average trade volume was 3.95 million shares over the past three months.
Xilio Therapeutics Inc (XLO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. XLO has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.37.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Xilio Therapeutics Inc (XLO) registered a 2.21% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.21% in intraday trading to $0.75, hitting a weekly high. The stock’s 5-day price performance is -5.57%, and it has moved by -16.38% in 30 days. Based on these gigs, the overall price performance for the year is 13.15%. The short interest in Xilio Therapeutics Inc (NASDAQ:XLO) is 0.58 million shares and it means that shorts have 0.3 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 89.29% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, XLO is trading at a discount of -833.33% off the target high and -833.33% off the low.
Xilio Therapeutics Inc (XLO) estimates and forecasts
In the rating firms’ projections, revenue will increase 714.94% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 23.2M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 3.7M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -11.55%. While earnings are projected to return 71.19% in 2025, the next five years will return 17.37% per annum.
XLO Dividends
Xilio Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
Xilio Therapeutics Inc insiders own 28.17% of total outstanding shares while institutional holders control 45.72%, with the float percentage being 63.65%. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the largest shareholder of the company, while 35.0 institutions own stock in it. As of 2024-06-30, the company held over 3.79 million shares (or 13.5618% of all shares), a total value of $3.59 million in shares.
The next largest institutional holding, with 3.0 million shares, is of ROCK SPRINGS CAPITAL MANAGEMENT LP’s that is approximately 10.7595% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.85 million.
Also, the Mutual Funds coming in first place with the largest holdings of Xilio Therapeutics Inc (XLO) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 739.56 shares. This amounts to just over 1.43 percent of the company’s overall shares, with a $0.55 million market value. The same data shows that the other fund manager holds slightly less at 177.49, or about 0.34% of the stock, which is worth about $0.13 million.
